Characteristic
All patients N=32 n (%)
Median age (range), years 61.5 (38-81)
Sex, n (%)
Female 15 (46.9)
Male 17 (53.1)
Race, n (%)
White 30 (93.8)
Unknown 2 (6.3)
ECOG performance status, n (%)
0 8 (25.0)
1 24 (75.0)
Primary site of cancer, n (%)
Colon 10 (31.3)
Lung 8 (25.0)
Esophagus 2 (6.3)
Oral cavity 2 (6.3)
Pancreas 2 (6.3)
Rectum 2 (6.3)
Bladder 1 (3.1)
Duodenum 1 (3.1)
Kidney 1 (3.1)
Skin melanoma 1 (3.1)
Small intestine 1 (3.1)
Uterus 1 (3.1)
Stage at study entry, n (%)
III 1 (3.1)
IIIB 2 (6.3)
IV 27 (84.4)
IVB 2 (6.3)
Type of lesion per investigator assessment at baseline, n (%)
Both target and non-target 22 (68.8)
Target only 10 (31.3)
Number of metastatic sites of cancer, median (range) 3 (1-7)
MET dysregulation
MET overexpression 24 (75)
MET amplification 14 (43.8)
MET mutation 3 (9.4)
Prior anti-cancer medications, n (%)
Any 32 (100)
Chemotherapy 31 (96.9)
Surgery 17 (53.1)
Radiotherapy 14 (43.8)
Number of prior chemotherapy regimens, n (%)
1 3 ( 9.4)
2 11 (34.4)
3 3 ( 9.4)
≥4 15 (46.9)
Type of last therapy, n (%)
Chemotherapy 19 (59.4)
Targeted therapy 7 (21.9)
Radiotherapy 3 (9.4)
Surgery 5 (15.6)
Other 6 (18.8)
Best response to last therapya, n (%)
Stable disease 3 (9.4)
Progressive disease 21 (65.6)
Not applicable 14 (43.8)
Unknown 2 (6.3)